Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03522844 · ClinicalTrials.gov registry record · Phase 4
Treatments for Anxiety: Meditation and Escitalopram
A Phase 4 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 4
- Development phase
- 276
- Enrollment target
NCT03522844 is a Phase 4 study that has completed, run by Georgetown University. The registered enrollment target is 276 participants.
The verdict
NCT03522844, a Phase 4 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 276 participants
- Enrollment target
Study Summary
We propose the first randomized, controlled study to assess the comparative effectiveness of Mindfulness-Based Stress Reduction (MBSR) with a medication for anxiety disorders. We will use escitalopram, gold-standard SSRI treatment for patients with anxiety disorders, and will examine the comparative effectiveness of the two treatments on anxiety symptoms and other outcomes important to patients.
Interventions
- DRUG Escitalopram
- OTHER Mindfulness-Based Stress Reduction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2018-06-18 |
| Est. Completion | 2022-01-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03522844
The ClinicalTrials.gov registry entry for NCT03522844 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Escitalopram is the first listed.
NCT03522844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03522844 about?
NCT03522844 is a clinical study titled "Treatments for Anxiety: Meditation and Escitalopram". We propose the first randomized, controlled study to assess the comparative effectiveness of Mindfulness-Based Stress Reduction (MBSR) with a medication for anxiety disorders. We will use escitalopram, gold-standard SSRI treatment for patients with anxiety disorders, and will examine the comparative...
What is the current status of trial NCT03522844?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 276 participants. The study started on 2018-06-18. Estimated completion is 2022-01-05.
What interventions are being tested in trial NCT03522844?
The interventions under investigation include: Escitalopram (DRUG), Mindfulness-Based Stress Reduction (OTHER).
Who is sponsoring clinical trial NCT03522844?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.